Animalcare Group PLC
LSE:ANCR

Watchlist Manager
Animalcare Group PLC Logo
Animalcare Group PLC
LSE:ANCR
Watchlist
Price: 246 GBX Market Closed
Market Cap: 148.5m GBX
Have any thoughts about
Animalcare Group PLC?
Write Note

Animalcare Group PLC
Accumulated Depreciation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Animalcare Group PLC
Accumulated Depreciation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accumulated Depreciation CAGR 3Y CAGR 5Y CAGR 10Y
Animalcare Group PLC
LSE:ANCR
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AstraZeneca PLC
LSE:AZN
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Verona Pharma PLC
NASDAQ:VRNA
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Accumulated Depreciation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Animalcare Group PLC
Glance View

Market Cap
148.5m GBX
Industry
Pharmaceuticals

Animalcare Group Plc engages in the development, sale, and supply of generic veterinary medicines and animal identification products. The company is headquartered in Ripon, North Yorkshire. The company went IPO on 2008-01-15. The firm is focused on developing and commercializing prescription and over-the-counter pharmaceutical products. The firm operates in three categories within the veterinary market, which includes Companion Animals, Equine and Production Animals. The company manages international supply chain, including specialist veterinary wholesalers and distributors. The firm develops, supplies and markets products and services to the veterinary profession. The company focuses on therapeutic areas, which includes pain management, dermatology and anti-infectives. The Company’s product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs.

ANCR Intrinsic Value
327.05 GBX
Undervaluation 25%
Intrinsic Value
Price

See Also

Back to Top